TY - JOUR
T1 - DCTN1 F52L mutation case of Perry syndrome with progressive supranuclear palsy-like tauopathy
AU - Honda, Hiroyuki
AU - Sasagasako, Naokazu
AU - Shen, Chang
AU - Shijo, Masahiro
AU - Hamasaki, Hideomi
AU - Suzuki, Satoshi O.
AU - Tsuboi, Yoshio
AU - Fujii, Naoki
AU - Iwaki, Toru
N1 - Funding Information:
The doctors thank Ms. Sachiko Koyama and Mr. Tsuyoshi Negi for their technical assistance, Dr. Takayasu Mishima for providing clinical data and pathological materials. We thank Wendy Brooks, PhD, from Edanz Group ( www.edanzediting.com/ac ) for English editing of a draft of this manuscript. Funding: Grant-in-Aid for Scientific Research ( 17K07097 and 26290017 ) from the Japan Society for the Promotion of Science (JSPS).
Publisher Copyright:
© 2018 Elsevier Ltd
PY - 2018/6
Y1 - 2018/6
N2 - Introduction: Perry syndrome is a rapidly progressive, autosomal dominant parkinsonism characterized by central hypoventilation, depression and severe weight loss. To date, eight DCTN1 mutations have been identified associated with Perry syndrome. A novel F52L DCTN1 mutation case of Perry syndrome is characterized by late-onset parkinsonism and frontotemporal atrophy. Methods: A Japanese woman suffered from slowly progressing parkinsonism since age 48. At age 59, she developed central hypoventilation, and required breathing assistance. Gene analysis identified a p.F52L mutation in DCTN1 and she was diagnosed with Perry syndrome. She died of aspiration pneumonia at age 74. Results: Postmortem examination revealed severe neuronal loss in the substantia nigra and the putamen. Immunohistochemistry for DCTN1 revealed many abnormal aggregates, mainly in neurons in the brainstem and basal ganglia. Additionally, numerous abnormal phosphorylated tau deposits including neurofibrillary tangles, tuft-shaped astrocytes and coiled bodies were observed mainly in the basal ganglia, brainstem and cerebellum. These correspond with the neuropathologic criteria for progressive supranuclear palsy. Colocalization of DCTN1 and tau were occasionally seen. Colocalization of phosphorylated α-synuclein and DCTN1 were also observed in Lewy body-like structures in oculomotor nuclei. Phosphorylated TARDBP-positive neuronal cytoplasmic inclusions were few. Conclusion: In conjunction with long disease duration and aging, our findings suggest that the F52L DCTN1 mutation may evoke severe tauopathy and moderate α-synucleinopathy.
AB - Introduction: Perry syndrome is a rapidly progressive, autosomal dominant parkinsonism characterized by central hypoventilation, depression and severe weight loss. To date, eight DCTN1 mutations have been identified associated with Perry syndrome. A novel F52L DCTN1 mutation case of Perry syndrome is characterized by late-onset parkinsonism and frontotemporal atrophy. Methods: A Japanese woman suffered from slowly progressing parkinsonism since age 48. At age 59, she developed central hypoventilation, and required breathing assistance. Gene analysis identified a p.F52L mutation in DCTN1 and she was diagnosed with Perry syndrome. She died of aspiration pneumonia at age 74. Results: Postmortem examination revealed severe neuronal loss in the substantia nigra and the putamen. Immunohistochemistry for DCTN1 revealed many abnormal aggregates, mainly in neurons in the brainstem and basal ganglia. Additionally, numerous abnormal phosphorylated tau deposits including neurofibrillary tangles, tuft-shaped astrocytes and coiled bodies were observed mainly in the basal ganglia, brainstem and cerebellum. These correspond with the neuropathologic criteria for progressive supranuclear palsy. Colocalization of DCTN1 and tau were occasionally seen. Colocalization of phosphorylated α-synuclein and DCTN1 were also observed in Lewy body-like structures in oculomotor nuclei. Phosphorylated TARDBP-positive neuronal cytoplasmic inclusions were few. Conclusion: In conjunction with long disease duration and aging, our findings suggest that the F52L DCTN1 mutation may evoke severe tauopathy and moderate α-synucleinopathy.
UR - http://www.scopus.com/inward/record.url?scp=85042627651&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85042627651&partnerID=8YFLogxK
U2 - 10.1016/j.parkreldis.2018.02.038
DO - 10.1016/j.parkreldis.2018.02.038
M3 - Article
C2 - 29499916
AN - SCOPUS:85042627651
SN - 1353-8020
VL - 51
SP - 105
EP - 110
JO - Parkinsonism and Related Disorders
JF - Parkinsonism and Related Disorders
ER -